Recursion Pharmaceuticals Inc. RXRX, Novavax Inc. NVAX and CRISPR Therapeutics AG CRSP are trending on Thursday. In ...

Nachrichten zur Vonovia Recursion Pharmaceuticals Registered (A) Aktie - Aktuelle Meldungen - Das sind die Expertenmeinungen ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar ...

Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel ...

Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share.

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and ...